Pfizer races to beat rivals for slice of $10bn respiratory jab market

  • 📰 IrishTimes
  • ⏱ Reading Time:
  • 34 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 98%

Canada News News

Canada Canada Latest News,Canada Canada Headlines

US pharma group says RSV vaccine is 86% effective at preventing severe disease

Pfizer said a late-stage trial in adults aged 60 years and older demonstrated that its vaccine was safe and effective at preventing serious disease from the virus. Photograph: Andrew Kelly/ReutersPfizer has said it will seek approval for a vaccine targeting respiratory syncytial virus in older adults after reporting positive trial data as rival groups race to develop a jab for a market that analysts estimate will generate up to $10 billion of annual sales.

An application for regulatory approval will be submitted in the autumn, said Pfizer, which is hunting for new ways to boost revenues as sales of Covid-19 vaccines begin to moderate. The virus is one of the few major infectious diseases without a vaccine, although recent scientific advances have encouraged four large pharmaceutical companies — Pfizer, GSK, Johnson & Johnson and Moderna — to undertake late-stage trials of potential jabs.

J&J expects to publish late-stage clinical data for its vaccine in the coming months as does Moderna, which is aiming to develop a single “multivalent” jab that would protect against RSV, influenza and Covid-19.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in CA

Canada Canada Latest News, Canada Canada Headlines